
## Lukas Delasos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5463104/publications.pdf Version: 2024-02-01



LUKAS DELASOS

#	Article	IF	CITATIONS
1	Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	11
2	New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature. Journal of Oncology Pharmacy Practice, 2021, 27, 716-721.	0.9	12
3	<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance. Clinical Cancer Research, 2021, 27, 799-806.	7.0	35
4	The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> Fusions. Clinical Cancer Research, 2021, 27, 3154-3166.	7.0	26
5	<scp>Membraneâ€based</scp> therapeutic plasma exchange: Hemodynamics and operational characteristics leading to procedure failure. Journal of Clinical Apheresis, 2021, 36, 841-848.	1.3	4
6	Primary central nervous system diffuse large Bâ€cell lymphoma masqueraded as Bingâ€Neel syndrome: Steps in management and review of future directions. Clinical Case Reports (discontinued), 2021, 9, e05113.	0.5	1
7	Primary Bone Lymphoma: A Case Series and Review of Literature. Case Reports in Hematology, 2020, 2020, 2020, 1-6.	0.4	15
8	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. Case Reports in Oncological Medicine, 2019, 2019, 1-6.	0.3	8
9	Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers. Cancer Discovery, 2018, 8, 686-695.	9.4	149